Market closed
Prothena/$PRTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prothena
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Ticker
$PRTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
163
Website
Prothena Metrics
BasicAdvanced
$495M
-
-$2.27
-0.03
-
Price and volume
Market cap
$495M
Beta
-0.03
52-week high
$25.42
52-week low
$9.10
Average daily volume
520K
Financial strength
Current ratio
10.008
Quick ratio
9.719
Long term debt to equity
1.691
Total debt to equity
2.227
Management effectiveness
Return on assets (TTM)
-15.54%
Return on equity (TTM)
-23.34%
Valuation
Price to revenue (TTM)
3.66
Price to book
1.02
Price to tangible book (TTM)
1.02
Price to free cash flow (TTM)
-3.29
Growth
Revenue change (TTM)
47.92%
Earnings per share change (TTM)
-17.67%
3-year revenue growth (CAGR)
-12.33%
3-year earnings per share growth (CAGR)
18.13%
What the Analysts think about Prothena
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Prothena Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Prothena Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Prothena News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Prothena stock?
Prothena (PRTA) has a market cap of $495M as of April 20, 2025.
What is the P/E ratio for Prothena stock?
The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of April 20, 2025.
Does Prothena stock pay dividends?
No, Prothena (PRTA) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Prothena dividend payment date?
Prothena (PRTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Prothena?
Prothena (PRTA) has a beta rating of -0.03. This means that it has an inverse relation to market volatility.